GLENN T FURUTA

Allopathic & Osteopathic Physicians|Pediatrics|Pediatric Gastroenterology AURORA, CO NPI 1194734962

General Payments — all program years on this page

$59,500.23

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 32
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $32,528.61 across 14 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Takeda Pharmaceuticals U.S.A., Inc. $15,651.519
SANOFI-AVENTIS U.S. LLC $10,185.102
Acerta Pharma LLC $2,600.001
GENZYME CORPORATION $2,574.001
Regeneron Pharmaceuticals, Inc. $1,518.001

By program year

Program yearAmountRecords
2018 $6,714.205
2019 $2,711.252
2020 $5,030.502
2021 $2,856.002
2022 $6,645.105
2023 $3,014.572
2024 $32,528.6114

Records — PY2024 (14)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1105566740 AstraZeneca Pharmaceuticals LP $2,600.00 11/27/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1114398937 Regeneron Pharmaceuticals, Inc. $1,518.00 01/08/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137551251 Takeda Pharmaceuticals U.S.A., Inc. $9,130.00 03/11/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137551253 Takeda Pharmaceuticals U.S.A., Inc. $60.00 03/12/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1137551255 Takeda Pharmaceuticals U.S.A., Inc. $28.65 03/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1137551257 Takeda Pharmaceuticals U.S.A., Inc. $38.63 03/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1137551259 Takeda Pharmaceuticals U.S.A., Inc. $2,490.00 04/05/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137551261 Takeda Pharmaceuticals U.S.A., Inc. $44.49 05/18/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1137551263 Takeda Pharmaceuticals U.S.A., Inc. $124.74 05/18/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1137551265 Takeda Pharmaceuticals U.S.A., Inc. $2,490.00 07/31/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137551267 Takeda Pharmaceuticals U.S.A., Inc. $1,245.00 12/18/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1139901308 SANOFI-AVENTIS U.S. LLC $5,092.55 05/26/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 View at CMS
1139901310 SANOFI-AVENTIS U.S. LLC $5,092.55 05/29/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 View at CMS
1139901370 GENZYME CORPORATION $2,574.00 05/02/2024 Consulting Fee Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.